Clinical course and outcomes in immunocompromised patients with neuroinfections
Close
Articolul precedent
Articolul urmator
291 1
Ultima descărcare din IBN:
2021-11-21 18:29
Căutarea după subiecte
similare conform CZU
616.8-022-036.83 (1)
Neurology. Neuropathology. Nervous system (971)
SM ISO690:2012
MANOLE, Elena, GROSU, Oxana, ODAINIC, Olesea, GAVRILIUC, Mihail. Clinical course and outcomes in immunocompromised patients with neuroinfections. In: 7th Congress of the Society of Neurologists Issue of the Republic of Moldova, Ed. 7, 16-18 septembrie 2021, Chişinău. Chişinău: Revista Curier Medical, 2021, Vol.64, p. 24. ISSN 2537-6381 (Online).
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
7th Congress of the Society of Neurologists Issue of the Republic of Moldova
Vol.64, 2021
Congresul "7th Congress of the Society of Neurologists Issue of the Republic of Moldova"
7, Chişinău, Moldova, 16-18 septembrie 2021

Clinical course and outcomes in immunocompromised patients with neuroinfections

CZU: 616.8-022-036.83

Pag. 24-24

Manole Elena1, Grosu Oxana2, Odainic Olesea2, Gavriliuc Mihail12
 
1 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
2 Diomid Gherman Institute of Neurology and Neurosurgery
 
Proiecte:
 
Disponibil în IBN: 27 septembrie 2021


Rezumat

Background: Medical conditions that weaken the immune system facilitate the development of the infections of the nervous system and modify its usual clinical pattern. The aim of our study was to analyze the clinical course and outcomes of immunocompromised patients with neuroinfections. Material and methods: A total number of 201 patients (101 (50%) – immunocompromised) with neuroinfections, collected for 11 years (from 2007 till 2018) in a tertiary neurological center were analyzed. The following conditions were considered to be an immunosuppressed state: age > 65 years, use of immunosuppressive drugs, a history of splenectomy, diabetes mellitus, alcoholism, HIV (human immunodeficiency virus) infected patients, malignancy, pregnancy, autoimmune diseases and systemic vasculitis. The SPSS program was used to perform the descriptive analysis. Results: Immunosuppressed patients were older (49±16.5 vs 39±13.6 years, p=0.000), mostly unemployed (65%, p<0.05), without any significant gender prevalence (men 57%). Encephalitis was the most prevalent syndrome in immunosuppressed (19% vs 6%, p<0.01) and meningitis – in immunocompetent patients (63% vs 49%, p<0.05) and had an abrupt onset in 28% of cases. Patients with immunosuppression had higher level of blood glucose (7.2 vs 5.83 mmol/l, p<0.001) and erythrocyte sedimentation rate (37 vs 27 mm/h, p=0.000). The mortality rate (28% vs 16%, p<0.05) and post-disease disability were noticed more frequently (40% vs 23%, p<0.01) in immunocompromised patients. Conclusions: Immunosuppression is frequent in patients with neuroinfections, delays diagnosis and leads to a high level of mortality and disability.

Cuvinte-cheie
neuroinfections, immunosuppression, Meningitis